Early Circulating Tumor DNA Dynamics Predict Fruquintinib Efficacy in Refractory Metastatic Colorectal Cancer Before Imaging - Top-Institutions - MDSpire

Early Circulating Tumor DNA Dynamics Predict Fruquintinib Efficacy in Refractory Metastatic Colorectal Cancer Before Imaging

  • By

  • Hou, Hebin

  • Liu, Pingping

  • Dong, Xiaohuan

  • Gai, Wei

  • Jiang, Peng

  • Yang, Fan

  • Hao, Chongli

  • May 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    BC Cancer
    BC Cancer

    Vancouver, British Columbia

    Key Differentiators

    • Oncology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Oncology

  • #3

    Stanford University
    Stanford University

    Stanford, California

    Key Differentiators

    • Oncology

  • #4

    University of British Columbia
    University of British Columbia

    Vancouver, British Columbia

    Key Differentiators

    • Oncology

  • #5

    Vall d’Hebron Institute of Oncology
    Vall d’Hebron Institute of Oncology

    Barcelona, Catalonia

    Key Differentiators

    • Oncology

Original Source(s)

Early Circulating Tumor DNA Dynamics Predict Fruquintinib Efficacy in Refractory Metastatic Colorectal Cancer Before Imaging

  • by Hou, Hebin , Liu, Pingping , Dong, Xiaohuan , Gai, Wei , Jiang, Peng , Yang, Fan , Hao, Chongli

  • May 20, 2026

Related Content

Case Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma

Circular RNAs as molecular bridges: dual regulation of ferroptosis and immunity in cancer

Who Decides How AI Enters Pathology?

Liron Pantanowitz explains why validation, leadership, and real-world use matter more than performance metrics